How You Can Profit From:
“An Oilfield in the Placenta”

May 2007 New Discovery Lets You Make A Fortune Without Ethical Controversy With Stem Cells From Umbilical Cord Blood Why you could pocket 30 times more profit from an obscure Israeli biotech discovery than from a 40 billion barrel oil find at Prudhoe Bay… By James Dale Davidson

If you have shied away from profiting from the immense promise of stem cells to treat disease because of moral concern over extracting stem cells from fetal tissue, pay close attention. You can now invest with a clear conscience. An Israeli entrepreneur, Zami Aberman, has discovered, "an oilfield in the placenta." His little company, Pluristem Life Systems (OTCBB: PLRS) has made a discovery which is potentially more valuable than Prudhoe Bay.

Sounds crazy, right? Not really. The exciting news is that you may be able to make more money from Pluristem’s "placental blood" stem cell discovery than you could have made four decades ago from ARCO’s discovery of a vast, untapped oil basin in Alaska’s remote Prudhoe Bay.

Back in 1968, when Atlantic Richfield, aka ARCO, discovered the Prudhoe Bay oil field, ARCO was already one of America’s largest oil companies. Its stock was selling for almost $100 per share. Even before the Prudhoe discovery, investors expected great things of ARCO, so most of its later success was already priced into the stock.

Yes, ARCO’s share price skyrocketed from $98.375 to $184.00 on news of what proved to be one of the major oil discoveries ever. The net result was that if you had rightly anticipated the discovery and invested soon enough, you could have almost doubled your money. $10,000 would have bought you about $100 shares of ARCO, which in turn, could have become $18,704, assuming no commission costs. So on an investment of $10,000 in 1968, you could have pocketed as much as $8,704 for anticipating the oil find of the century.

Doesn’t sound like much to get excited about, does it? Making $8,704 would hardly change your life. This is why it is actually misleading to compare Pluristem’s placental stem cell discoveries with striking oil, even a 40 billion-barrel field. The Pluristem opportunity really doesn’t compare – because it is so much bigger.

The advantage you gain by investing in Pluristem now is that no one has ever made a fortune from placental (also known as UBC) stem cells before. They are an obscure variation on a biotech opportunity that most investors don't yet understand. Investors in 1968 knew that finding a multi-billion barrel oil field meant big cash flow to come. But most investors today have a much harder time imagining the huge potential revenues which could be Pluristem's reward for becoming the first biotech company based on UBC placental stem cells.

Take a close look at the potential upside from an investment of $10,000 in Pluristem today. At the recent price of 12 cents per share, you could get about 83,000 shares of PLRS with a $10,000 investment. If Pluristem's promising treatments for blood cancer are validated in forthcoming FDA trials, (expected to begin late this year) that would open the door to an immediate market of $2 billion annually for Pluristem's patented PLX-1 process for growing and expanding Mesenchymal Stromal Cells (MSC) from the placenta.

MSCs are potent cells that differentiate into many different body tissues, such as muscle, nerve, cartilage, and even bone marrow.

In pre-clinical studies, the PLX-1 process has been proven to increase umbilical cord (UBC) stem cell effectiveness by up to 500%.

This could be important as a "gusher" of the biotech revolution, a source of profit for you, and a way to alleviate a lot of human misery.

Here's why. Umbilical cord (UBC) stem cells have been used as a non-standard treatment in place of traditional bone marrow transplants to treat deadly disease, like leukemia. The problem has been that it has taken much longer (40 days) for UBC stem cells to engraft as compared to a traditional bone marrow transplant (15 days).

Patients with compromised (or totally destroyed) immune systems don't always have an extra several weeks to lie around waiting for UBC stem cells to work. PLX-1 changes the equation, increasing the number of UBC stem cells; improving the effectiveness of grafts, and shortening recovery times.

Pluristem's PLX-1 solution targets an unmet need in more than 100,000 blood cancer patients annually. With the improved speed and effectiveness of grafting promised by PLX-1, UBC stem cells have many other advantages over bone marrow transplants.

• UBC stem cells, augmented with PLX-1, would be much cheaper. The average cost of a bone marrow transplant from a non-related donor is $95,000, Pluristem's Zami Aberman estimates that he can cut the transplant cost to $30,000, including $15,000 for Pluristem's PLX-1 product.
• UBC stem cells are less developed and can be used with a less precise genetic match than bone marrow transplants. More than 95% of patients seeking a stem cell transplant could expect to find a cord blood sample match.
• UBC stem cells can be frozen and kept ready for use on short notice. By contrast, it can cost $25,000 to $50,000 and take a year or more to sort through potential donors for matched adult tissue.
• UBC stem cells are much less likely to cause Graft-Versus-Host Disease (GVHD), than similarly matched adult tissue. In about 12% of all bone marrow transplants, the patient experiences rejection of transplanted tissue and dies.

If Pluristem's PLX-1 proves as effective in human trials as it has in pre-clinical trials on mice, this will open new horizons for leukemia patients and sufferers of other afflictions, possibly including Alzheimer's and Parkinson's.

Success in treating leukemia with UBC stem cells would encourage efforts to employ them in other applications where mesenchymal stem cells (MSCs) from bone marrow have proven clinically helpful. There could be $30 billion in other markets for Pluristem's unique Placenta eXpanded (PLX) cells derived from the PluriX technology.

Biotech experts suggest that successful tests of the PLX cells would make Pluristem a billion dollar company. That's not a sure thing. But consider what kind of profit you could make if it happened. An investment of $10,000 in PLRS at the recent price of $0.12 could turn into more than a quarter of a million dollars.

This is not as far-fetched as it might seem judging by the PLRS's current low stock price. According to independent analysts, JM Dutton & Associates, Pluristem is significantly undervalued compared to biotech competitors working to commercialize stem cell products.

These above-mentioned companies have a market value of from 5.3X to 15X more than Pluristem. This underscores Pluristem's potential to be a fortune-making investment.

Your $10,000 investment now could bring you a profit of more than a quarter of a million dollars.

Don't miss your chance to get your position in this fortune-making opportunity before the market catches on to the huge profit potential of Pluristem and its patented 3-D Plurix bioreactor, the only technology in existence capable of large scale expansion of UCB stem cells without differentiation. (Once the cells differentiate, they cannot be transplanted into the patient.)

If it pans out as I expect, you could make 40 times more profit by investing in Pluristem than shrewd investors made in 1968 on one of the greatest oil finds of the 20th century. Pluristem’s placental stem cell discoveries bring the promise of life to the dying without compromising morals in any way. No fetus is harmed. No life is impaired.

To the contrary, Pluristem represents the promise of life at its best. Don't let it pass you by. The result could be better treatment for leukemia, a new approach to harnessing stem cells to treat disease without moral controversy, and a fortune for you.

Buy Pluristem (PLRS.OB) now, and profit from the stem cell revolution.

Sincerely,

James Davidson